Expedia stock surges as results top Street view

Referenced Symbols

Expedia Group Inc. EXPE, -3.57% shares rallied in the extended session Thursday after the online travel company’s results came in better than expected. Expedia shares jumped 5% after hours, following a 3.6% decline in the regular session to close at $164.82. The company reported a first-quarter loss of $606 million, or $4.17 a share, compared with $1.3 billion, or $9.24 a share, in the year-ago period. The adjusted loss, which exclude stock-based compensation expenses and other items, was $2.02 a share, compared with $1.83 a share in the year-ago period. Revenue fell to $1.25 billion from $2.21 billion in the year-ago quarter. Analysts surveyed by FactSet had forecast a loss of $2.30 a share on revenue of $1.11 billion. “Travel remains a study in contrasts – with strong vacation rental growth and demand for domestic travel continuing to drive us forward, while demand for international and business travel and conventional lodging remain challenged,” said Expedia Chief Executive Peter Kern in a statement. “As the vaccine rollout continues, we expect to see a now familiar story play out; domestic and leisure demand lead the recovery. However, as the dire situation in India reminds us, in some markets, things may get worse before they get better.”

Read Next

Read Next

Moderna reports $1.7 billion in COVID-19 vaccine sales, posts first profit ever

Moderna Inc. undefined brought in $1.7 billion in sales of its COVID-19 vaccine in the first quarter of 2021, marking the company's first significant billion-dollar revenue haul this year and also the first time it's ever reported a GAAP profit. Moderna had earnings of $1.2 billion, or $2.84 per share, in the first quarter of 2021. This is compared to a loss of $124 million, or 35 cents per share, in the first quarter a year ago. The FactSet consensus was $2.39. Moderna had revenue of $1.9 billion for the quarter, up from $8 million in the same quarter a year ago. The FactSet consensus for revenue was $2.0 billion. This quarter marked the first time that the company has generated product revenue during the first three months of the year. About $1.7 billion of that came from sales of its COVID-19 vaccine. (Before receiving authorization from the Food and Drug Administration, it generated grant and collaboration revenue.) Moderna's stock is up 55.8% for the year, while the S&P 500 undefined has gained 10.9%.

More On MarketWatch

About the Author